Illumina TruSight Tumor 170

Illumina has launched TruSight Tumor 170, a next-generation sequencing-based panel that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes. The panel analyzes both DNA and RNA and requires 40 nanograms of input from formalin-fixed paraffin-embedded samples. The panel will begin shipping in the first quarter 2017 for research use only.


BioMérieux EMAG

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.